Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jun 18 04:00PM ET
0.9970
Dollar change
+0.0170
Percentage change
1.73
%
Index- P/E- EPS (ttm)-1.00 Insider Own2.19% Shs Outstand40.00M Perf Week-4.13%
Market Cap39.88M Forward P/E- EPS next Y-0.07 Insider Trans0.00% Shs Float39.13M Perf Month0.04%
Income-22.56M PEG- EPS next Q-0.11 Inst Own1.93% Short Float2.75% Perf Quarter-31.24%
Sales0.00M P/S- EPS this Y57.87% Inst Trans-4.25% Short Ratio2.25 Perf Half Y-44.61%
Book/sh-0.07 P/B- EPS next Y82.67% ROA-85.79% Short Interest1.08M Perf Year-14.79%
Cash/sh0.32 P/C3.15 EPS next 5Y55.20% ROE-555.68% 52W Range0.81 - 3.02 Perf YTD-43.67%
Dividend Est.- P/FCF- EPS past 5Y29.27% ROIC-76.89% 52W High-66.99% Beta2.82
Dividend TTM- Quick Ratio3.58 Sales past 5Y- Gross Margin- 52W Low23.39% ATR (14)0.06
Dividend Ex-Date- Current Ratio3.72 EPS Y/Y TTM62.29% Oper. Margin- RSI (14)48.85 Volatility2.23% 2.67%
Employees9 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q68.79% Payout- Rel Volume0.50 Prev Close0.98
Sales Surprise- EPS Surprise28.57% Sales Q/Q- EarningsMay 13 BMO Avg Volume477.57K Price1.00
SMA201.90% SMA50-3.93% SMA200-26.07% Trades Volume237,318 Change1.73%
Date Action Analyst Rating Change Price Target Change
May-28-21Upgrade Gabelli & Co Sell → Hold
Mar-15-21Upgrade H.C. Wainwright Neutral → Buy $2.50
Jun-02-20Downgrade RBC Capital Mkts Outperform → Sector Perform $7 → $2
Jan-21-20Downgrade Gabelli & Co Buy → Sell
Dec-11-19Downgrade SVB Leerink Outperform → Mkt Perform
Jun-21-19Initiated H.C. Wainwright Buy $17
Jun-11-25 07:00AM
May-19-25 07:00AM
May-14-25 03:08AM
02:52AM
May-13-25 07:00AM
07:00AM Loading…
May-06-25 07:00AM
Apr-30-25 04:30PM
Apr-29-25 08:00AM
Apr-14-25 08:00AM
Feb-08-25 02:06AM
12:16AM
Feb-07-25 07:00AM
Jan-31-25 08:00AM
Nov-21-24 08:30AM
Nov-15-24 02:10AM
07:00AM Loading…
Nov-14-24 07:00AM
Nov-11-24 08:00AM
Oct-28-24 10:19AM
07:49AM
05:00AM
Oct-25-24 11:03AM
Oct-10-24 08:30AM
Oct-09-24 05:00PM
Sep-24-24 10:33AM
Sep-10-24 07:00AM
Sep-06-24 04:30PM
Aug-17-24 08:09AM
Aug-14-24 07:00AM
Aug-10-24 08:18AM
Aug-07-24 04:30PM
05:30PM Loading…
Aug-06-24 05:30PM
Aug-02-24 08:00AM
Jul-22-24 07:30AM
Jun-21-24 08:00AM
Jun-05-24 08:00AM
May-31-24 08:00AM
May-14-24 08:21AM
May-13-24 10:49PM
11:53AM
07:00AM
May-06-24 08:00AM
Apr-29-24 08:00AM
Apr-02-24 10:22AM
Mar-29-24 12:09AM
Mar-28-24 11:53AM
07:00AM
Mar-21-24 04:30PM
Mar-15-24 08:00AM
Mar-07-24 07:57AM
Mar-06-24 08:00AM
Feb-01-24 03:03PM
Jan-30-24 07:00AM
Dec-04-23 08:00AM
Nov-15-23 12:22PM
12:08AM
Nov-14-23 07:00AM
Nov-07-23 08:30AM
Oct-24-23 08:00AM
Oct-12-23 09:15AM
Aug-11-23 10:10PM
07:00AM
Aug-04-23 05:00PM
Jun-27-23 09:50AM
Jun-21-23 08:35AM
Jun-12-23 06:23PM
May-12-23 07:00AM
May-10-23 09:16AM
Apr-20-23 05:00PM
Apr-13-23 12:00PM
Mar-18-23 02:06AM
Mar-16-23 09:16PM
07:00AM
Mar-09-23 05:00PM
Jan-11-23 06:00PM
Dec-15-22 08:00AM
Nov-10-22 07:00AM
Nov-03-22 08:00AM
Oct-20-22 07:30AM
Oct-17-22 05:19PM
Sep-19-22 07:30AM
Sep-07-22 09:15AM
Sep-01-22 04:15PM
Aug-17-22 09:45AM
Aug-16-22 09:00PM
Aug-12-22 07:00AM
Jul-11-22 02:31PM
07:30AM
Jul-06-22 04:30PM
Jun-14-22 05:00PM
May-13-22 07:00AM
May-11-22 08:00AM
Apr-25-22 05:06PM
Mar-28-22 10:19AM
07:00AM
Mar-21-22 08:00AM
Mar-10-22 08:00AM
Feb-08-22 05:00PM
Dec-14-21 04:30PM
07:12AM
Dec-13-21 08:00AM
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.